Deivanayagam N, Nedunchelian K, Ahamed S S, Rathnam S R
Advanced Center for Clinical Epidemiological Research & Training (ACCERT), Madras Medical College, India.
Bull World Health Organ. 1993;71(3-4):307-9.
A case-control study was carried out between May 1988 and May 1989 to assess the effectiveness of three doses of trivalent oral poliomyelitis vaccine (TOPV3) in children aged 6-35 months in Madras city. All the cases were patients with acute paralytic poliomyelitis who were residing in Madras city and were hospitalized in the Institute of Child Health; they represented 95% of such cases in the city. The diagnosis was based on clinical grounds and confirmed by stool culture which was positive in 60%. Age- and sex-matched controls, all residing in the city of Madras, were recruited concurrently from the Institute's outpatient department. There were 78 cases and 315 controls. Vaccine efficacy observed for TOPV3 was 81% (95% CI, 58-91%) for the 6-35-month age group and 86% (95% CI, 67-94%) for the 6-23-month age group. Vaccine efficacy, after controlling for age using the Mantel-Haenszel method, was 83% (95% CI, 67-91%). An unimmunized child was at 5 times greater risk of developing acute paralytic poliomyelitis than a fully immunized child.
1988年5月至1989年5月期间,开展了一项病例对照研究,以评估三价口服脊髓灰质炎疫苗(TOPV3)三剂次对马德拉斯市6至35个月大儿童的有效性。所有病例均为居住在马德拉斯市且在儿童健康研究所住院的急性麻痹性脊髓灰质炎患者;他们占该市此类病例的95%。诊断基于临床依据,并经粪便培养确诊,粪便培养阳性率为60%。年龄和性别匹配的对照者均居住在马德拉斯市,同时从该研究所门诊部招募。共有78例病例和315名对照者。在6至35个月年龄组中,观察到TOPV3的疫苗效力为81%(95%CI,58 - 91%),在6至23个月年龄组中为86%(95%CI,67 - 94%)。使用Mantel-Haenszel方法控制年龄后,疫苗效力为83%(95%CI,67 - 91%)。未接种疫苗的儿童患急性麻痹性脊髓灰质炎的风险是完全接种疫苗儿童的5倍。